At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 214 enrolled
Drug / intervention
Bimekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab for Psoriatic Arthritis. Completed, enrolled 214 participants across 47 sites in 6 countries.
Detailed Summary
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesCzechia, Germany, Hungary, Poland, Russia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
First PostedOct 2019
Primary CompletionNov 2020
Study CompletionNov 2020
TodayJul 2026
First PostedOct 1, 2019
Enrollment StartAug 13, 2019
Primary CompletionNov 5, 2020
Study CompletionNov 13, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.8 years ago
Interventions
Bimekizumabdrug
Study participants will receive bimekizumab at pre-specified time points.